Last Updated: June 29, 2026

GLYCEROL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Glycerol

A generic version of GLYCEROL was approved as glycerol phenylbutyrate by PH HEALTH on December 2nd, 2021.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for GLYCEROL?
  • What are the global sales for GLYCEROL?
  • What is Average Wholesale Price for GLYCEROL?
Summary for GLYCEROL
US Patents:0
Applicants:6
NDAs:6
DailyMed Link:GLYCEROL at DailyMed
Drug patent expirations by year for GLYCEROL

US Patents and Regulatory Information for GLYCEROL

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 220313-001 Apr 15, 2026 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Navinta Llc GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 220568-001 Apr 23, 2026 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lupin GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 207694-001 Apr 30, 2026 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Msn GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 219540-001 Apr 15, 2026 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Inc GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 218738-001 Apr 15, 2026 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ph Health GLYCEROL PHENYLBUTYRATE glycerol phenylbutyrate LIQUID;ORAL 205742-001 Dec 2, 2021 AA RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links